Tentt

Gilead to Acquire Ouro Medicines for Autoimmune

Announced
HealthcareOther

Deal Overview

Gilead Sciences agreed to acquire Ouro Medicines to expand its autoimmune therapy portfolio. The article frames the transaction as a strategic expansion within Gilead’s autoimmune and immunology focus.

Key Details

Transaction
Gilead Sciences acquires Ouro Medicines
Deal Size
Over $100M

Filed under

Source

Read full article on news.google.com

via GN - entered into definitive agreement · March 24, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →